|
Ginkgolide B does not affect PGE2-induced loss of synaptophysin. |
|||
| Synaptophysin content (units) |
|||
|
|
|||
| Pre-treatment |
|||
|
|
|||
| None |
Ginkgolide B (1 μM) |
AH13205 (100 nM) |
|
| None |
100 ± 5 |
101 ± 3 |
102 ± 3 |
| Aβ1–42 (200 nM) |
24 ± 4 |
93 ± 7 |
97 ± 6 |
| PAF (10 nM) |
33 ± 7 |
78 ± 5 |
89 ± 8 |
| PGE2 (40 nM) |
41 ± 6 |
44 ± 7 |
96 ± 4 |
| Butaprost (1 μM) |
29 ± 5 |
37 ± 11 |
94 ± 7 |
| Misprostal (1 μM) |
32 ± 7 |
34 ± 6 |
98 ± 5 |
|
The effects of pre-treatment with ginkgolide B, or with the EP receptor antagonist AH13205 on the synaptophysin content of neuronal cultures incubated for 24 hours with Aβ1–42, PAF, PGE2, or with the EP receptors agonists butaprost or misoprostol as shown. Values shown are the mean synaptophysin content ± SD from 9 observations. | |||
Bate et al. Molecular Neurodegeneration 2008 3:1 doi:10.1186/1750-1326-3-1 |
|||